嵌合抗原受体
免疫原性
体内
融合蛋白
二氢叶酸还原酶
生物
免疫系统
蛋白质水解
细胞
细胞生物学
体外
T细胞
计算生物学
生物化学
酶
免疫学
重组DNA
基因
遗传学
作者
Iris K. Lee,Nitika Sharma,Estela Noguera-Ortega,Maria Liousia,Miren L. Baroja,Jean M. Etersque,Jonathan Pham,Swarbhanu Sarkar,Beatriz M. Carreno,Gerald P. Linette,Ellen Puré,Steven Μ. Albelda,Mark A. Sellmyer
标识
DOI:10.1016/j.ymthe.2023.10.020
摘要
Chimeric antigen receptor (CAR) T cell therapy has been successful for hematological malignancies. Still, a lack of efficacy and potential toxicities have slowed its application for other indications. Furthermore, CAR T cells undergo dynamic expansion and contraction in vivo that cannot be easily predicted or controlled. Therefore, the safety and utility of such therapies could be enhanced by engineered mechanisms that engender reversible control and quantitative monitoring. Here, we use a genetic tag based on the enzyme Escherichia coli dihydrofolate reductase (eDHFR), and derivatives of trimethoprim (TMP) to modulate and monitor CAR expression and T cell activity. We fused eDHFR to the CAR C terminus, allowing regulation with TMP-based proteolysis-targeting chimeric small molecules (PROTACs). Fusion of eDHFR to the CAR does not interfere with cell signaling or its cytotoxic function, and the addition of TMP-based PROTACs results in a reversible and dose-dependent inhibition of CAR activity via the proteosome. We show the regulation of CAR expression in vivo and demonstrate imaging of the cells with TMP radiotracers. In vitro immunogenicity assays using primary human immune cells and overlapping peptide fragments of eDHFR showed no memory immune repertoire for eDHFR. Overall, this translationally-orientied approach allows for temporal monitoring and image-guided control of cell-based therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI